Publicaciones en las que colabora con JOSÉ ÁNGEL GARCÍA SÁENZ (16)

2013

  1. Circulating tumor cells following first chemotherapy cycle: An early and strong predictor of outcome in patients with metastatic breast cancer

    Oncologist, Vol. 18, Núm. 8, pp. 917-923

2011

  1. Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer

    Breast Cancer Research and Treatment, Vol. 128, Núm. 1, pp. 127-136

  2. Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: Efficacy and cardiac safety from the GEICAM/2004-05 study

    Annals of Oncology, Vol. 22, Núm. 12, pp. 2591-2596

  3. Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review

    Clinical and Translational Oncology, Vol. 13, Núm. 2, pp. 121-132

2010

  1. Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study

    Breast Cancer Research and Treatment, Vol. 122, Núm. 1, pp. 169-176

2009

  1. Circulating tumor cells in metastatic breast cancer: Timing of blood extraction for analysis

    Anticancer Research, Vol. 29, Núm. 10, pp. 4185-4187

  2. Circulating tumour cells in locally advanced breast cancer

    Clinical and Translational Oncology, Vol. 11, Núm. 8, pp. 544-547

2008

  1. Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refractory breast cancer

    Journal of Chemotherapy, Vol. 20, Núm. 5, pp. 632-639

2007

  1. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial

    Lancet Oncology, Vol. 8, Núm. 3, pp. 219-225

2006

  1. Circulating tumoral cells lack circadian-rhythm in hospitalized metastasic breast cancer patients

    Clinical and Translational Oncology, Vol. 8, Núm. 11, pp. 826-829

  2. Significance of the immunohistochemical detection of lymph node micrometastases in Stage II Colorectal Carcinoma

    Clinical and Translational Oncology, Vol. 8, Núm. 9, pp. 676-680

2005

  1. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer

    Clinical Breast Cancer, Vol. 6, Núm. 4, pp. 325-329

2004

  1. Phase II study of pegylated liposomal doxorubicin plus vinorelbine in breast cancer with previous anthracycline exposure

    Clinical Breast Cancer, Vol. 5, Núm. 5, pp. 353-357

2003

  1. Vinorelbine as a 96-hour continuous infusion in heavily pretreated patients with metastatic breast cancer: A Cooperative Study by the GEICAM Group

    Clinical Breast Cancer, Vol. 3, Núm. 6, pp. 399-404

2002

  1. Immediate vs. delayed imipenem treatment in cancer patients with profound neutropenia induced by high-dose chemotherapy: Results of a randomized study

    Revista Espanola de Quimioterapia, Vol. 15, Núm. 3, pp. 257-263

2000

  1. Consolidation treatment after first line therapy in advanced ovarian cancer

    Oncologia